本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Hsinchu, Taiwan – March 20, 2025 – ACE Biotek unveiled its Spark Surgical Anesthesia System at the 2025 Kaohsiung SmartCity Summit & Expo, featured at the Smart Healthcare Pavilion. The company also participated in the Joint Commission of Taiwan’s “Smart Hospital Leadership Summit,” where it engaged with over a hundred hospital directors across Taiwan, promoting the vision of enhancing healthcare efficiency and reducing labor burdens through innovative healthcare solutions. Themed “Sustainability × AI = The New Future of Smart Healthcare,” the Smart Healthcare Pavilion gathered 18 medical institutions from Southern Taiwan, showcasing innovative achievements in competent healthcare across the central and southern regions. ACE Biotek’s Spark Surgical Anesthesia System, which integrates pre-, intra-, and post-operative anesthesia care forms, aims to enhance the digitalization level of anesthesia departments in hospitals across these regions. The interactive demonstration area attracted numerous healthcare professionals to experience the system firsthand. The event drew officials from various industries, academia, and the healthcare sector to the opening ceremony and nearly 200 international visitors. Many guests, such as Kaohsiung Deputy Mayor Lin Chin-Rong, the Ministry of Health and Welfare Director, Health Bureau representatives, and hospital IT managers, visited the ACE Biotek booth to explore the Spark Surgical Anesthesia System. By leveraging digital technologies, the system achieves structured data management and paperless processes, significantly improving healthcare efficiency and precision in collaboration. Additionally, it offers a comprehensive integration of anesthesia data throughout the surgical process, from physiological monitors to anesthesia machine data, providing real-time recording and seamless data flow. This high-level integration enables smooth interfacing with hospital HIS, surgical systems, and billing systems while combining medical AI and big data to enhance operational efficiency and accuracy, supporting hospitals in achieving efficient and standardized intelligent surgery management. In line with the Ministry of Health and Welfare’s vision for a next-generation digital healthcare platform, ACE Biotek is dedicated to developing practical, innovative hospital solutions tailored for domestic hospitals and promoting them internationally in countries such as Japan, the Middle East, and Southeast Asia. ACE Biotek’s Japan office in Izumi City will hold its grand opening ceremony on April 15, showcasing its commitment to global expansion. ACE Biotek will focus on implementing AI-powered innovative healthcare solutions and collaborating with Japanese medical institutions and partners to bring Taiwan’s imaginative hospital achievements to the international stage. About ACE Biotek Established in 2000, ACE Group has grown across wireless and healthcare industries for more than 20 years. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. To achieve the early diagnosis of diseases, we have developed innovative medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. In the long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies in transforming into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd. Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park) Phone: +886-3-5500909 E-mail: service@acebiotek.com Website: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
台灣新竹，2025年3月20日 – 筑波醫電開發Spark手術麻醉系統，受邀參加2025高雄智慧城市展於智慧醫療主題館中亮相，並參與醫策會「智慧醫院院長大會」，與全台超過百位醫院院長共同切磋交流，響應以智慧醫療提升照護效率、降低人力負擔。本次主題館以「永續×AI = 智慧醫療新未來」為主題，匯聚南台灣18家醫療院所，展示中南部智慧醫療的創新成果。筑波醫電Spark手術麻醉系統以「整合手術前、中、後麻醉護理表單」為特色，提升中南部醫院麻醉科的數位化水平，展會設有互動體驗區，吸引眾多醫界專業人士駐足。 本次活動吸引產、醫、學界的長官出席開幕儀式，並迎來全球近200位海外訪客。許多嘉賓如高雄副市長林欽榮、衛福部司長、衛生局、醫院資訊主管等親臨筑波醫電攤位，體驗Spark手術麻醉系統。該系統透過電子化技術實現數據結構化與無紙化管理，大幅提升醫療效率與協作精準度，為醫師、護理師及檢查人員帶來極大便利。此外，全面整合手術過程的麻醉數據，從生理監視器到麻醉機資料，實現即時記錄與完整數據流轉。透過高度整合能靈活對接醫院HIS、手術與批價系統，並結合醫療AI大數據，提升作業效率與準確性，助力醫院實現智慧手術的高效化與標準化管理。 為響應衛福部次世代數位醫療平台的宗旨，筑波醫電致力於開發可落地國內醫院的的智慧醫院系統方案，並已在日本、中東、東南亞等國家進行推廣。筑波醫電的日本辦事處位於出水市，將於4月15日舉行揭牌開幕式，展現公司國際化的步伐。未來將專注於將AI智慧醫療方案落地，並與日本醫療院所及合作夥伴攜手，將台灣智慧醫院的成果推向國際。 關於筑波醫電ACE Biotek 筑波醫電大樓是董事長許深福先生驅動內心的寄望及理念，依據建築設計師、施工團隊及同仁們很科學的作品。是筑波人多年來文化、創意技術的展現，是筑波全體同仁長久對生醫產業接軌國際平台的堅持。筑波科技集團以豐富的無線通訊軟硬體整合經驗、結合半導體晶片、醫學影像演算法、雲端技術、人工智慧、臨床醫師專業、法規驗證與專利技術綜效，著力於人們早期病變篩檢系統的精準醫療設備產品研發與生產。期望不但可以減少病患及家人的遺憾，並開拓台灣本土精密無創微創醫檢設備能量且推廣於國際，更建立台灣從3C到三醫(醫才、醫技、醫材)的產業鏈轉型平台與人才的培育之目標。 連絡筑波醫電 筑波醫電股份有限公司Advanced ACE Biotek Co., Ltd. 地址：30261新竹縣竹北市生醫二路66號 (新竹生醫園區) 電話: +886-3-5500909 E-mail: service@acebiotek.com 網站: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
保必歐®是首款在台灣市場核准納入全民健康保險給付，用於治療復發/難治性多發性骨髓瘤（R/R MM）成年病人的XPO1抑制劑。 這是繼中國大陸、韓國、澳洲和新加坡之後，公司在第五個亞太市場實現對於保必歐®的核准納入全民健康保險用藥品項。 公司預計保必歐®將在亞太地區更多市場獲得健保用藥品項的收錄。 上海和香港2025年2月14日 /美通社/ -- 致力於研發，生產和銷售同類首款及/或同類最優血液及實體腫瘤療法的商業化階段領先創新生物製藥公司–德琪醫藥有限公司（簡稱「德琪醫藥」，香港交易所股票代碼：6996.HK）今日宣佈，保必歐®（英文商品名：XPOVIO，學名：selinexor）在台灣市場核准納入全民健康保險給付，與bortezomib 和dexamethasone (XVd方案) 合併使用於先前已接受至少2種治療失敗的復發/難治性多發性骨髓瘤（R/R MM）成年病人。保必歐®將於2025年3月1日起正式納入台灣市場《全民健康保險用藥品項表》。 保必歐®是全球首個全新機制的口服選擇性XPO1抑制劑，已在亞太市場的9個國家和地區核准用於治療多項適應症，並在其中5個市場（中國大陸和台灣市場、澳洲、新加坡和韓國）納入健保給付。公司預計保必歐®將在亞太地區更多市場獲得健保用藥品項的收錄。 多發性骨髓瘤（MM）是一種源自體內漿細胞異常增生導致的惡性疾病。研究報告顯示，MM在台灣是血液系統第二大常見的惡性腫瘤，每年新增約700至800例MM患者及400例相關死亡。[1]多數患者都面臨著易復發、生存期短、治療選擇有限的困境。此次保必歐®成功在台灣市場獲得健保給付，將進一步減輕患者經濟負擔，惠及更多患者及其家庭。 在持續推進亞太市場佈局的同時，公司也正努力擴充保必歐®的適應症範圍。基於其獨特的作用機制，公司正在開發保必歐®在骨髓纖維化（MF）和子宮內膜癌 (EC) 等不同疾病領域的多種合併療法。 關於保必歐®（XPOVIO） 保必歐®是全球首個全新機制的口服選擇性核輸出蛋白（XPO1）抑制劑，具有「全新機制、協同增效、快速起效、持久緩解」四大特點。 通過抑制核輸出蛋白XPO1，保必歐®可促使腫瘤抑制蛋白和其他生長調節蛋白在細胞核內儲留和活化，並將低細胞質內多種致癌蛋白濃度。保必歐®發揮抗腫瘤作用機制的三種途徑為：1）透過誘導腫瘤抑制蛋白在細胞核內累積，發揮抗腫瘤作用；2）藉由致癌蛋白mRNA在細胞核內積累，降低細胞質內致癌蛋白濃度；3）透過活化糖皮質激素受體（GR）路徑，恢復賀爾蒙敏感性。基於其獨特的作用機制，保必歐®在不同疾病領域的多種合併療法正在進行開發。目前，德琪醫藥正在中國大陸地區執行多項（其中三項全球臨床試驗由德琪醫藥與Karyopharm Therapeutics Inc.[納斯達克交易所股票代碼：KPTI] 共同執行）針對復發/難治性血液及實體腫瘤的臨床研究。 關於德琪醫藥 德琪醫藥有限公司（簡稱「德琪醫藥」，香港交易所股票代碼：6996.HK）是一家以研發為驅動，並已進入商業化階段的生物製藥領先企業，以「醫者無疆，創新永續」為願景，德琪醫藥專注於血液及實體腫瘤領域的同類首款和同類最優療法的早期研發、臨床研究、藥物生產及商業化，致力於通過提供突破性療法，改善全球患者生活品質。 自2017年以來，德琪醫藥現已建立起一條擁有9款從臨床延展至商業化階段的腫瘤藥物資產研發管道，其中，6款產品具有全球權利，3款產品具有亞太權利。公司已在美國及多個亞太市場獲得31個新藥臨床試驗申請（IND）核准，並提交了10個新藥上市申請（NDA）。目前，保必歐®（XPOVIO）已獲得中國大陸、台灣、香港和澳門市場，以及韓國、新加坡、馬來西亞、泰國和澳大利亞的新藥上市核准。 前瞻性陳述 本文所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請細閱本文，並理解我們的實際未來業績或表現可能與預期有重大差異。本文內有關任何董事或本公司意向的陳述或提述乃於本文刊發日期作出。任何該等意向均可能因未來發展而出現變動。有關這些因素和其他可能導致未來業績與任何前瞻性聲明存在重大差異的因素的進一步討論，請參閱我們截至2023年12月31日的公司年報中描述的其他風險和不確定性，以及之後向香港證券交易所提交的文件。 參考文獻 2022 Cancer Registry Annual Report, Health Promotion Administration of Taiwan Ministry of Health and Welfare 更多信息，敬請垂詢： 投資者聯繫人：龍振國 郵箱：Donald.Lung@antengene.com 手機：+86 18420672158 媒體聯繫人：錢偉郵箱：Peter.Qian@antengene.com 手機：+86 13062747000
SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered with CGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nine countries, including Mexico, Switzerland, and India. Led by Professor Jin-Sung Kim (also known as Luke) of Seoul St. Mary's Hospital, The Catholic University of Korea — a world-renowned expert in minimally invasive and endoscopic spine surgery — the program showcased Korea's leadership in advanced surgical techniques and medical device innovation. CG MedTech and CGBIO Showcase Korea’s Spine Surgery Excellence to Global Experts The training course featured advanced spine model simulators from Germany, Canada, and Italy. These simulators replicated human anatomical structures, including blood vessels, muscles, bones, and ligaments, providing participants with an unparalleled hands-on experience. The program focused on full-endoscopic and biportal endoscopic spine surgery, a minimally invasive technique that reduces recovery time and complications while enabling precise, multi-angle access. The involvement of global simulator manufacturers highlights the growing recognition of Korea's expertise in spine surgery.Participants engaged in practical sessions led by Professors Jin-Sung Kim, Sang Hyun Han, and Jung Hoon Kim, which featured cutting-edge Korean medical devices. These included CG MedTech's Anax MIS System, designed for precise pedicle screw placement with minimal tissue disruption, and CGBIO's NOVOSIS, a bone substitute celebrated for its biocompatibility and effectiveness. Also showcased were CGDERM Spinkle, an anti-adhesion agent enhancing surgical safety, and the Excender expandable cage, praised for its innovative design that restores disc height and angle, even in challenging surgical environments."CG MedTech, with CGBIO, is committed to advancing global medical education by sharing innovative surgical methods and premium devices," said Ju Mi Chung, CEO of CG MedTech. "Our mission is to enhance the skills of medical professionals worldwide while strengthening Korea's leadership in this field."The event, hosted by the Catholic University of Korea (International Skills Center), received support from the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The Regional Domestic Medical Device Education and Training Support Center—Korea's first comprehensive training hub for medical devices—played a vital role in bridging government initiatives with industry collaboration.Programs like this firmly establish Korea as a global hub for advanced medical technology and education. The collaboration between CG MedTech, CGBIO, and international institutions reaffirms Korea's commitment to innovation and its leadership in spine surgery education and technology. CG MedTech and CGBIO Showcase Korea’s Spine Surgery Excellence to Global Experts
TAIPEI, Nov. 1, 2024 /PRNewswire/ -- TPIsoftware (7781) and Taipei Medical Alliance signed a Memorandum of Understanding on October 30 in a collaborative effort to advance healthcare technology and medical academia. The collaboration aims to facilitate digital transformation and AI innovation in healthcare and clinical services through efficient resource sharing. Regular seminars, training sessions and academic events are to be expected in order to deepen medical expertise and accelerate digitalization within the healthcare sector. Prominent attendees include incumbent Deputy Minister of Health and Welfare Jen-Der Lue, former Deputy Minister Pi-Sheng Wang and former legislator Shih-Ying Tsai, along with representatives from leading medical institutions and organizations, such as The National Federation of Long-Term Care, Taiwan Medical Association, Taiwan Society of Aesthetic Plastic Surgery and the College of Medicine at National Chung Hsing University. "This initiative brings together experts across diverse fields to pool resources and complement one another's strengths, which is targeted to ultimately improve the quality of healthcare services in Taiwan," commented Chung-Chieh Chao, Chairman of Taipei Medical Alliance, highlighting TPIsoftware's specialties in successful digital transformation. "The implementation of AI-powered chatbots, modernization of hospital information systems and cloud transformation, along with Fast Healthcare Interoperability Resources (FHIR) launched by the Ministry of Health and Welfare that fosters seamless healthcare information exchange rely on a tech partner with extensive experience in digitalization to build integrated healthcare management." Chairman of TPIsoftware Ben Yao stated, "Teaming up with Taipei Medical Alliance shows our commitment to improving medical management and healthcare services. With over 15 years of experience transforming and modernizing digital financial services, we have solidified our foothold in Taiwan and overseas markets. We have been emerging into the healthcare sector by helping large-scale organizations implement digital strategies. We pride ourselves in helping clients deliver pain-free, seamless system upgrades without having to go through the hassle and disruptions. The use of AI chatbots ranges from booking an appointment online to making health-related queries and reviewing prescription guidelines. An integrated healthcare service platform enables access to patients' medical history for accurate diagnoses, with a health management platform that monitors pre- and post-treatment data for better understanding of patient conditions. Through the alliance, we make a concerted effort towards strengthening the physician-patient relationship, improving digital health initiatives and data sharing with innovative technology.
TAIPEI, Nov. 1, 2024 /PRNewswire/ -- TPIsoftware (7781) and Taipei Medical Alliance signed a Memorandum of Understanding on October 30 in a collaborative effort to advance healthcare technology and medical academia. The collaboration aims to facilitate digital transformation and AI innovation in healthcare and clinical services through efficient resource sharing. Regular seminars, training sessions and academic events are to be expected in order to deepen medical expertise and accelerate digitalization within the healthcare sector. Prominent attendees include incumbent Deputy Minister of Health and Welfare Jen-Der Lue, former Deputy Minister Pi-Sheng Wang and former legislator Shih-Ying Tsai, along with representatives from leading medical institutions and organizations, such as The National Federation of Long-Term Care, Taiwan Medical Association, Taiwan Society of Aesthetic Plastic Surgery and the College of Medicine at National Chung Hsing University. "This initiative brings together experts across diverse fields to pool resources and complement one another's strengths, which is targeted to ultimately improve the quality of healthcare services in Taiwan," commented Chung-Chieh Chao, Chairman of Taipei Medical Alliance, highlighting TPIsoftware's specialties in successful digital transformation. "The implementation of AI-powered chatbots, modernization of hospital information systems and cloud transformation, along with Fast Healthcare Interoperability Resources (FHIR) launched by the Ministry of Health and Welfare that fosters seamless healthcare information exchange rely on a tech partner with extensive experience in digitalization to build integrated healthcare management." Chairman of TPIsoftware Ben Yao stated, "Teaming up with Taipei Medical Alliance shows our commitment to improving medical management and healthcare services. With over 15 years of experience transforming and modernizing digital financial services, we have solidified our foothold in Taiwan and overseas markets. We have been emerging into the healthcare sector by helping large-scale organizations implement digital strategies. We pride ourselves in helping clients deliver pain-free, seamless system upgrades without having to go through the hassle and disruptions. The use of AI chatbots ranges from booking an appointment online to making health-related queries and reviewing prescription guidelines. An integrated healthcare service platform enables access to patients' medical history for accurate diagnoses, with a health management platform that monitors pre- and post-treatment data for better understanding of patient conditions. Through the alliance, we make a concerted effort towards strengthening the physician-patient relationship, improving digital health initiatives and data sharing with innovative technology. About TPIsoftware TPIsoftware is the No. 1 digital transformation software company in Taiwan, renowned for our formidable software development capabilities, modular design, and AI-driven technologies. We provide proprietary iPaaS middle platform DigiFusion, conversational AI series SysTalk.ai, sustainability management platform ESGswift, and enterprise security platform GadoSecurity to domestic and overseas markets. With extensive experiences in cross-national, large-scale projects, our robust R&D capability has earned the trust of customers across industries. Subscribe to Newsletter | Website | Facebook | LinkedIn
Ministry of Health and Welfare
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
